Antiviral HIV-1 SERINC restriction factors disrupt virus membrane asymmetry

The host proteins SERINC3 and SERINC5 are HIV-1 restriction factors that reduce infectivity when incorporated into the viral envelope. The HIV-1 accessory protein Nef abrogates incorporation of SERINCs via binding to intracellular loop 4 (ICL4). Here, we determine cryoEM maps of full-length human SERINC3 and an ICL4 deletion construct, which reveal that hSERINC3 is comprised of two α-helical bundles connected by a ~ 40-residue, highly tilted, “crossmember” helix. The design resembles non-ATP-dependent lipid transporters. Consistently, purified hSERINCs reconstituted into proteoliposomes induce flipping of phosphatidylserine (PS), phosphatidylethanolamine and phosphatidylcholine. Furthermore, SERINC3, SERINC5 and the scramblase TMEM16F expose PS on the surface of HIV-1 and reduce infectivity, with similar results in MLV. SERINC effects in HIV-1 and MLV are counteracted by Nef and GlycoGag, respectively. Our results demonstrate that SERINCs are membrane transporters that flip lipids, resulting in a loss of membrane asymmetry that is strongly correlated with changes in Env conformation and loss of infectivity.

D D The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement D D A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly □ □ The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
D D A description of all covariates tested D D A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons D D A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) □ □ For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted

) smFRET data were analyzed using Matlab (MathWorks, version R2017a) and a custom Matab-based analysis software package SPARTAN (version 3.8.1), courtesy of Scott Blanchard, and custom Matlab scripts, developed in the Mothes lab
Flipping assays: FluoEssence v3.9 was used for fluorescence vs time measurements. . (v. Mothes-7.01/Yeager 9.4.1) For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data
Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: -Accession codes, unique identifiers, or web links for publicly available datasets -A description of any restrictions on data availability -For clinical datasets or third party data, please ensure that the statement adheres to our QQ.)ky_ X X X X X X X X X X X X X D Confirm that both raw and final processed data have been deposited in a public database such as GEO.

Atomic coordinates and EM maps for WT hSERINC3-Fab and
D Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.

Data access links
For "Initial submission" or "Revised version" documents, provide reviewer access links. For your "Final submission" document, May remain private before publication. provide a link to the deposited data.

Files in database submission
Genome browser session (e.g. UCSC) Provide a list of all files available in the database submission.
Provide a link to an anonymized genome browser session for "Initial submission" and "Revised version" documents only, to enable peer review. Write "no longer app/icab/e"for "Final submission" documents.

Methodology
Replicates Describe the experimental replicates, specifying number, type and replicate agreement.

Sequencing depth
Describe the sequencing depth for each experiment, providing the total number of reads, uniquely mapped reads, length of reads and whether they were paired-or single-end.

Antibodies
Describe the antibodies used for the ChlP-seq experiments; as applicable, provide supplier name, catalog number, clone name, and Jot number.
Peak calling parameters Specify the command line program and parameters used for read mapping and peak calling, including the Ch IP, control and index files used.

Data quality
Describe the methods used to ensure data quality in full detail, including how many peaks are at FDR 5% and above 5-fo/d enrichment.

Software
Describe the software used to collect and analyze the Ch IP-seq data. For custom code that has been deposited into a community repository, provide accession details.

Sample preparation
Instrument Software Cell population abundance Gating strategy D Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.

Experimental design
Design type Indicate task or resting state; event-related or block design. l )